Cytogen initiates prostate cancer study

The trial will specifically examine people with progressive hormone-refractory prostate cancer who have failed docetaxel-based regimens.

The primary objective of the study is to determine if there is an improvement in four-month progression-free survival for the combination regimen versus Quadramet therapy alone. Currently, there is no standard of care for treating prostate cancer patients who have progressive disease following docetaxel-based therapy.

Quadramet is a targeted radiopharmaceutical that is approved for treating pain arising from cancer that has spread to the bone. PSA-TRICOM is a targeted cancer vaccine under development at the NIH and designed to enhance immune system response against tumor cells.

This combination approach is supported by positive preclinical findings that support the combination of Quadramet and cancer vaccines for the treatment of prostate, breast, lung, and other cancers.

“To date, single-agent immune-based strategies for treating cancer have shown limited promise for treating well-established tumors or advanced disease,” said Michael Becker, president and CEO of Cytogen.

“Published studies indicate that multimodality approaches incorporating immunotherapy, radiotherapy, and other approaches hold the greatest promise for clinical success.”